Page 1

INTERIM REPORT JANUARY - SEPTEMBER 2021 Q3 BONESUPPORT ™ ● JULY - SEPTEMBER 2021 • Net sales increased by 14 percent ( 26 percent at constant exchange rates ' ) and amounted to SEK 54.9 million ( 48.1 ) . • The North America ( NA ) segment reported a sales increase of 16 percent ( 34 percent at constant exchange rate ) . • The Europe & Rest of the World ( EUROW ) segment reported a sales increase of 12 percent ( 16 percent at constant exchange rates ) . ● • The gross margin amounted to 89.0 percent ( 91.4 ) . Operating result amounted to SEK -13.3 million ( -19.2 ) . Earnings per share , before and after dilution , were SEK -0.22 ( -0.33 ) . EVENTS DURING THE PERIOD • In September , the company announced that the results of the company's Investigational Device Exemption ( IDE ) study FORTIFY are in - conclusive , due to high drop out rate . ● BEST SALES QUARTER TO DATE • In September , it was announced that the company had submitted a supplemental De Novo application to the US Food and Drug Administration ( FDA ) to obtain market approval for the company's antibiotic - releasing product CERAMENT® G , for the indication bone infection . During the third quarter , BONESUPPORT's board of directors executed the mandate from the annual general meeting earlier this year , entering into a share swap agreement with a third party bank amounting till SEK 62.3 million , to ensure delivery of performance shares to participants in the long - term incentive programs decided by the same AGM . KEY FIGURES Net sales , SEKm Sales growth , % ¹ Gross profit , SEKm Gross margin , % ¹ Operating loss , SEKm Loss for the period , SEKm Equity at period end , SEKM Net debt , SEKm¹ Operating cash flow , SEKM Cash at period end , SEKm Earnings per share before and after dilution , SEK Jul - Sep 2021 54.9 14.1 48.8 89.0 -13.3 -14.1 284.9 -214.5 -20.2 225.5 -0.22 JANUARY - SEPTEMBER 2021 • Net sales increased by 19 percent ( 31 percent at constant exchange rates ) and amounted to SEK 151.5 million ( 127.7 ) . • The North America ( NA ) segment reported a sales increase of 22 percent ( 41 percent at constant exchange rate ) . • The Europe & Rest of the World ( EUROW ) segment reported a sales increase of 14 percent ( 18 percent at constant exchange rates ) . • The gross margin amounted to 89.0 percent ( 89.2 ) . • Operating result amounted to SEK -58.9 million ( -71.9 ) . Earnings per share , before and after dilution , were SEK -0.96 ( -1.28 ) . ● EVENTS AFTER THE PERIOD • In October , it was announced that Michael Wrang Mortensen will join the company in the newly established role of Executive Vice President ( EVP ) Research & Development ( R & D ) and Operations on December 1 , 2021. At the same time , Dr. Michael Diefenbeck is leaving the responsibility for R & D to fully focus on his role as Chief Medical Officer and EVP Medical & Clinical Affairs , and Johan Olsson is leaving his role as EVP Manufacturing & Supply , transitioning to a role as Senior Advisor . • In October , a kit with cannula and guide tubes was launched for application and use of CERAMENT for skeletal injuries in close proximity to joints . These products open up a market segment in the US of approximately an additional 20,000 procedures per year . 2020 48.1 22.9 44.0 91.4 -19.2 -21.2 425.1 -367.3 -19.0 377.9 -0.33 Jan - Sep 2021 151.5 18.6 134.9 89.0 -58.9 -61.3 284.9 -214.5 -66.7 225.5 -0.96 2020 127.7 16.9 113.8 89.2 -71.9 -74.2 425.1 -367.3 -78.7 377.9 -1.28 12 months LTM 204.7 17.7 182.6 89.2 -85.6 -88.5 284.9 -214.5 -88.3 225.5 -1.38 2020 180.9 16.3 161.6 89.4 -98.6 -101.4 398.9 -343.3 -100.3 353.7 -1.72 This information is such information as BONESUPPORT AB ( publ ) is obliged to make public pursuant to EU's regulation on market abuse ( MAR ) and the Swedish Securities Markets Act . 1 APM : Alternative performance measures , see definitions on page 23 .